Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | $-135M | $-136M | $-112M | -65.8% | -51.2% | -26.8% |
| 2024 | $14M | $-177M | $-186M | $-124M | -58.4% | -78.5% | 15.7% |
| 2023 | $64M | $-172M | $-161M | $-138M | -43.7% | -34.0% | -42.9% |
| 2022 | $96M | $-295M | $-282M | $-284M | -58.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 6.65 |
| Operating Revenue | 6.65 |
| Operating Expense | 154.35 |
| Research And Development | 107.83 |
| Selling General And Administration | 46.52 |
| Total Expenses | 154.35 |
| Operating Income | -147.70 |
| Total Operating Income As Reported | -147.70 |
| EBITDA | -134.80 |
| Normalized EBITDA | -135.05 |
| EBIT | -147.70 |
| Interest Income | 11.05 |
| Interest Expense | - |
| Net Interest Income | 11.05 |
| Other Non Operating Income Expenses | 0.09 |
| Other Income Expense | 0.34 |
| Interest Income Non Operating | 11.05 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 11.05 |
| Pretax Income | -136.32 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -136.32 |
| Net Income From Continuing And Discontinued Operation | -136.32 |
| Net Income From Continuing Operation Net Minority Interest | -136.32 |
| Net Income | -136.32 |
| Net Income Common Stockholders | -136.32 |
| Net Income Including Noncontrolling Interests | -136.32 |
| Normalized Income | -136.56 |
| Diluted NI Availto Com Stockholders | -136.32 |
| Basic Average Shares | 118.79 |
| Diluted Average Shares | 118.79 |
| Reconciled Depreciation | 12.90 |
| Total Unusual Items | 0.24 |
| Total Unusual Items Excluding Goodwill | 0.24 |
| Special Income Charges | 0 |
| Impairment Of Capital Assets | 0 |
| Gain On Sale Of Security | 0.24 |
| General And Administrative Expense | 46.52 |
| Other Gand A | 46.52 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Fate Therapeutics, Inc.this co. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Nuvectis Pharma, Inc. | NVCT |
| - |
| - |
| - |
| - |
| - |
| - |
| $257M |
| -9.70 |
| 13.93 |
| -143.6% |
| - |
| Codexis, Inc. | CDXS | $255M | -5.79 | 5.04 | -87.0% | -8.18 |
| Sight Sciences, Inc. | SGHT | $250M | -6.51 | 3.91 | -60.1% | -6.07 |
| Protara Therapeutics, Inc. | TARA | $248M | -4.32 | 1.26 | -29.2% | -3.14 |
| Coherus Oncology, Inc. | CHRS | $243M | 1.45 | 3.98 | 275.4% | -1.14 |
| Peer Median | - | -5.71 | 3.95 | -47.9% | -2.33 | |